After eight-straight monthly losses starting in April 2023, the shares of pharmaceutical concern Bristol-Meyers Squibb Co (NYSE:BMY) started to rebound in December, though were swiftly rejected by the 80-day moving average at the start of the year. Now, it looks like that bounce was indeed short-lived, as BMY is seeing even more pressure on the charts after its recent dip.
According to Schaeffer's Senior Quantitative Analyst Rocky White, Bristol-Meyers stock is within one standard deviation of its 50-day and 60-day moving averages. The equity has seen six similar signals from its 60-day trendline, after which the stock was negative one month later every time, averaging a 4.8% loss. Its 60-day trendline has seen seven other signals, and the stock was negative one month later 86% of the time, averaging a 3.5% drop.
Short interest has been unwinding, down 17.9% over the last month, now representing a slim 1.1% of the stock's available float. The stock failed to capitalize on the short covering, however, indicating technical weakness.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
